[{"NetIncomeLoss_1_Q3_USD":-73643000.0,"DueFromRelatedPartiesCurrent_0_Q3_USD":48909000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q3_USD":15088000.0,"CommitmentsAndContingencies_0_Q3_USD":null,"InterestPaidNet_3_Q3_USD":20287000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":122000.0,"PaymentsOfLoanCosts_3_Q3_USD":11470000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-41647000.0,"StockIssuedDuringPeriodValueNewIssues_3_Q3_USD":139915000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q3_USD":987000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3_Q3_USD":8935000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":1000.0,"AssetsCurrent_0_Q3_USD":450724000.0,"OtherNoncashIncomeExpense_3_Q3_USD":42000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":63303000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_3_Q3_USD":337556000.0,"SellingGeneralAndAdministrativeExpense_3_Q3_USD":78606000.0,"SellingGeneralAndAdministrativeExpense_1_Q3_USD":27501000.0,"ProceedsFromIssuanceOfLongTermDebt_3_Q3_USD":380000000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":13242000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q3_shares":14739000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_3_Q3_USD":960000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":24000.0,"IncomeTaxesPaidNet_3_Q3_USD":14000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3_Q3_USD":281318000.0,"CommonStockSharesIssued_0_Q3_shares":63956000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q3_USD":307678000.0,"Assets_0_Q3_USD":512188000.0,"ShareBasedCompensation_3_Q3_USD":47425000.0,"IncreaseDecreaseInPrepaidExpensesOther_3_Q3_USD":2274000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":44391000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":61881000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"ResearchAndDevelopmentExpense_1_Q3_USD":67371000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0_Q3_USD":1000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":61881000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":63303000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":-178000.0,"GainsLossesOnExtinguishmentOfDebt_3_Q3_USD":-15464000.0,"ProceedsFromStockPlans_3_Q3_USD":2545000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":2033000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":1235000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":279000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":93000.0,"CommonStockValue_0_Q3_USD":1000.0,"InterestPayableCurrent_0_Q3_USD":5791000.0,"ConvertibleLongTermNotesPayable_0_Q3_USD":226695000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":262342000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_0_Q3_USD":1000.0,"RestrictedCash_0_Q3_USD":833000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_3_Q3_USD":19928000.0,"OtherPrepaidExpenseCurrent_0_Q3_USD":10308000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-219606000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-73801000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":2133000.0,"OtherAssetsNoncurrent_0_Q3_USD":810000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":93282000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":47823000.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_3_Q3_USD":265000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-158000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":-23000.0,"OtherDepreciationAndAmortization_3_Q3_USD":5394000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":195788000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0,"RepaymentsOfNotesPayable_3_Q3_USD":235347000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-219304000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-73550000.0,"DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_0_Q3_USD":0.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_3_Q3_USD":35000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3_Q3_USD":8935000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3_Q3_USD":47425000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":15564000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-185478000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3_Q3_USD":19900000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":62361000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":63717000.0,"PaymentsToAcquireProductiveAssets_3_Q3_USD":5372000.0,"LiabilitiesCurrent_0_Q3_USD":104270000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":126000.0,"AccountsPayableCurrent_0_Q3_USD":6442000.0,"InterestExpense_3_Q3_USD":32905000.0,"InterestExpense_1_Q3_USD":11573000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":94115000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":960000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":6732000.0,"FinanceLeaseRightOfUseAssetAmortization_3_Q3_USD":2213000.0,"IncreaseDecreaseInOtherOperatingAssets_3_Q3_USD":-541000.0,"AdditionalPaidInCapital_0_Q3_USD":1206524000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3_Q3_USD":2545000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0_Q3_USD":15088000.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":15430000.0,"NetIncomeLoss_3_Q3_USD":-219583000.0,"PaymentsOfDebtIssuanceCosts_3_Q3_USD":5326000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":139915000.0,"IncomeLossFromEquityMethodInvestments_1_Q3_USD":13403000.0,"RestrictedCashNoncurrent_0_Q3_USD":833000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.0,"CommonStockSharesAuthorized_0_Q3_shares":200000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":53127000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":18257000.0,"OperatingIncomeLoss_3_Q3_USD":-221267000.0,"OperatingIncomeLoss_1_Q3_USD":-76615000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q3_USD":265065000.0,"IncreaseDecreaseInInterestPayableNet_3_Q3_USD":132000.0,"IncreaseDecreaseInIncomeTaxesReceivable_3_Q3_USD":-37000.0,"ContractWithCustomerLiabilityCurrent_0_Q3_USD":18204000.0,"PreferredStockValue_0_Q3_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":512188000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":30472000.0,"IncomeLossFromEquityMethodInvestments_3_Q3_USD":48299000.0,"PreferredStockSharesAuthorized_0_Q3_shares":230000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":47425000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":9685000.0,"OperatingExpenses_3_Q3_USD":274394000.0,"OperatingExpenses_1_Q3_USD":94872000.0,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-1.16,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-3.55,"OtherLiabilitiesNoncurrent_0_Q3_USD":9704000.0,"StockholdersEquity_0_Q3_USD":-261536000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q3_USD":750000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":307553000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-1468183000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":35218000.0,"CommonStockSharesOutstanding_0_Q3_shares":63956000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":15564000.0,"IncreaseDecreaseInContractWithCustomerLiability_3_Q3_USD":-19382000.0,"Ticker":"TBPH","CIK":"1583107","name":"THERAVANCE BIOPHARMA, INC.","OfficialName":"Theravance Biopharma Inc. Ordinary Shares","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"688048421.0","Country":"Cayman Islands","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201109"}]